SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLASs Phase 3 REGAL trial reaching its 80-death trigger and moving to final analysis has put the pending GPS survival readout at the center of discussion. Traders are split between optimism about a potential benefit and concern over the sharp selloff and lack of immediate data; claims that the decline reflects manipulation remain speculation.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Marvells announced all-stock acquisition of Lumentum has prompted a sharp selloff, with many traders criticizing the deals scale and expected shareholder dilution. Others see strategic value in combining Marvells connectivity products with Lumentums optical technology for AI data centers, leaving the debate focused on near-term costs versus potential long-term benefits.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Marvells agreed all-stock acquisition of Lumentum is driving attention, with shareholders focused on the fixed exchange ratio that ties LITEs value to Marvells share price until the deal closes. Many traders criticize the terms and the long wait, while others see strategic value in combining Marvells connectivity business with Lumentums AI-optics technology.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMDs upcoming Q3 earnings and guidance are dominating discussion after Intels disappointing report sparked a sharp spillover selloff across semiconductors. Traders are split between viewing the decline as sympathy selling ahead of a potentially stronger AMD report and fearing broader chip-demand or AI-spending risks.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apples fiscal Q4 earnings report is the main focus, with traders weighing iPhone and Duo demand and holiday-quarter guidance against rising memory costs and margin pressure. The community is split between expectations for a strong report and concerns that the stocks run-up and high valuation could bring a sell-the-news reaction.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

Traders are focused on Compasss expected completion of the rolling COMP360 NDA submission, speculating that confirmation could start an accelerated FDA review; many are frustrated by the wait and see the filing update as a key catalyst. Recent weakness is attributed by some to broader biotech pressure, while Usonas parallel psilocybin filing raises competitive concerns for others; skeptics counter that Usona is pursuing MDD and lacks Compasss commercial infrastructure.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

FDA accelerated approval of Inovios competing RRP treatment has intensified concerns about competition for Precigens PAPZIMEOS and coincided with a sharp selloff. Traders debate whether the rivals dosing protocol will draw patients away or whether PAPZIMEOSs commercial head start, established coverage, and full approval will help it retain an advantage.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

AXSM is drawing attention after its quarterly results beat expectations, but shares sold off as traders focused on the lack of quantified guidance, high expenses, and uncertainty about when the company will reach cash-flow break-even. Some investors see Auvelitys growth as evidence of improving fundamentals, while others argue that the unclear outlook and launch questions outweigh the strong report.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracles planned stock and bond offerings to fund its AI and data-center buildout are weighing on shares, with traders concerned about dilution, rising debt and whether the spending will generate returns. Some argue the financing was already disclosed and is part of a defined investment plan, while others view its timing as a sign of mounting funding pressure.

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Tempus AI Inc. - Ordinary Shares - Class A

Tempus AI Inc

Tempus AI is drawing attention after reporting better-than-expected third-quarter results and raising the lower end of its full-year revenue outlook, with growth in oncology testing and its data business supporting the upbeat reaction. Traders are broadly positive on the beat-and-raise, though some expect volatile trading or a post-earnings pullback.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Ever wonder what the actual inflection point looks like before it&#39;s obvious in the chart? For $EMAT it might be this, a confirmed non-China feedstock chain, an exec order mandating exactly that supply profile, and a company small enough that institutional money hasn&#39;t had a reason to look yet.

StockTwits Web

Evolution Metals & Technologies Corp. Common Stock

Ever wonder what the actual inflection point looks like before it's obvious in the chart? For 

 it might be this, a confirmed non-China feedstock chain, an exec order mandating exactly that supply profile, and a company small enough that institutional money hasn't had a reason to look yet.